Company Overview
ImageneBio, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing therapeutics for patients suffering from immunological, autoimmune, and inflammatory diseases. The company functions within the broader healthcare sector, specifically the biotechnology industry, which focuses on the discovery and development of new medical treatments and technologies. ImageneBio currently employs 15 individuals and holds a market capitalization of $55.92M, generating $800,000 in annual revenue according to trailing twelve-month figures. The combination of a $55.92M market cap and $800,000 in revenue indicates that the company is a micro-cap entity with a relatively small market footprint, reflecting its early-stage development status where significant capital is required before substantial revenue generation occurs.
Financial Health
ImageneBio reported revenue of $800,000 over the trailing twelve months, yet recorded a net income of $-52,395,000 and an EBITDA of $-48,052,000. The substantial gap between the minimal revenue of $800,000 and the significant net loss of $-52,395,000 reveals a cost structure heavily driven by research and development expenses rather than sales operations, which is typical for clinical-stage biotechnology firms. The company generated free cash flow of $-18,874,876, indicating a continuous burn rate that consumes cash reserves to fund ongoing clinical trials and operational needs. Despite the negative operating margin of -6056.4% and a profit margin of 0.0%, the company maintains a gross margin of 100.0%, suggesting that the cost of goods sold is negligible compared to revenue, likely due to the intangible nature of drug development assets. ImageneBio holds $135.35M in cash against $2.98M in debt, resulting in a debt-to-equity ratio of 2.23, which presents a unique balance sheet profile where high leverage exists but is largely offset by an abundant cash position. The current ratio stands at 12.49, indicating that the company possesses a very strong ability to meet its short-term liabilities with its current assets, providing ample liquidity buffer for its operations. Furthermore, the return on equity is -68.9% and the return on assets is -35.9%, metrics that reflect the dilutive impact of losses on shareholder value and the efficiency of asset utilization in the absence of profitability.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the negative net income, while the forward P/E is listed as -1.49, implying that the market expects earnings to remain negative or for the company to continue operating at a loss in the near term. The price-to-book ratio is 0.42, indicating that the stock is trading at a significant discount to its book value, which often occurs with speculative biotech companies where future potential is priced differently than historical assets. Investors may also look at the price-to-sales ratio of 69.91 and the EV/EBITDA of 1.59 as alternative valuation metrics, as these figures suggest the market is valuing the company primarily on its potential pipeline rather than current financial performance. The stock has a 52-week high of $18.00 and a 52-week low of $3.94, and without a specific current share price provided in the facts, the valuation context relies on these volatility extremes to show the range of investor sentiment over the past year. The beta value is N/A, meaning there is no available historical data to quantify the company's volatility relative to the broader market, which is common for smaller biotechnology firms that may not have sufficient trading volume for standard beta calculations.
Growth & Income
ImageneBio reports revenue growth year-over-year as N/A and earnings growth year-over-year as N/A, as the company has not yet achieved consistent growth patterns typical of mature businesses. Since the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings and cash flows are theoretically available for reinvestment into the company's growth initiatives rather than being distributed to shareholders. The absence of a dividend yield confirms that ImageneBio follows a standard biotechnology growth model where capital is retained to fund expensive clinical trials and regulatory approvals. Consequently, the overall growth and income profile is characterized by a focus on capital appreciation through product development rather than current income generation or dividend payouts.